252 related articles for article (PubMed ID: 24033119)
21. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
22. Computational studies of Fe(III) binding to bryostatins, bryostatin analogs, siderophores and marine natural products: arguments for ferric complexes in medicinal applications.
Manning TJ; Thomas J; Osiro S; Smith J; Abadi G; Noble L; Phillips D
Nat Prod Res; 2008 Mar; 22(5):399-413. PubMed ID: 18404560
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.
Irie K; Yanagita RC
Chem Rec; 2014 Apr; 14(2):251-67. PubMed ID: 24677503
[TBL] [Abstract][Full Text] [Related]
24. [Advance of several types of important marine antitumor drugs].
Zhang JY; Fu LW
Yao Xue Xue Bao; 2008 May; 43(5):435-42. PubMed ID: 18717327
[TBL] [Abstract][Full Text] [Related]
25. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
26. Chemistry and clinical biology of the bryostatins.
Mutter R; Wills M
Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129
[TBL] [Abstract][Full Text] [Related]
27. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs.
Wender PA; Horan JC; Verma VA
Org Lett; 2006 Nov; 8(23):5299-302. PubMed ID: 17078702
[TBL] [Abstract][Full Text] [Related]
28. Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold.
Wender PA; Staveness D
Org Lett; 2014 Oct; 16(19):5140-3. PubMed ID: 25238640
[TBL] [Abstract][Full Text] [Related]
29. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
30. Analysis of long-term cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response.
Wang D; Darwish DS; Schreurs BG; Alkon DL
Behav Pharmacol; 2008 May; 19(3):245-56. PubMed ID: 18469542
[TBL] [Abstract][Full Text] [Related]
31. Microtubule-targeting anticancer agents from marine natural substance.
Liu Z; Xu P; Wu T; Zeng W
Anticancer Agents Med Chem; 2014 Mar; 14(3):409-17. PubMed ID: 24533652
[TBL] [Abstract][Full Text] [Related]
32. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
34. Total synthesis of bryostatin 3.
Trost BM; Wang Y; Buckl AK; Huang Z; Nguyen MH; Kuzmina O
Science; 2020 May; 368(6494):1007-1011. PubMed ID: 32467391
[TBL] [Abstract][Full Text] [Related]
35. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
36. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu A; Lazo JS
Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725
[TBL] [Abstract][Full Text] [Related]
37. Gold from the sea: marine compounds as inhibitors of the hallmarks of cancer.
Schumacher M; Kelkel M; Dicato M; Diederich M
Biotechnol Adv; 2011; 29(5):531-47. PubMed ID: 21371549
[TBL] [Abstract][Full Text] [Related]
38. Structural modifications of bryostatin 2.
Pettit GR; Sengupta D; Blumberg PM; Lewin NE; Schmidt JM; Kraft AS
Anticancer Drug Des; 1992 Apr; 7(2):101-14. PubMed ID: 1575884
[TBL] [Abstract][Full Text] [Related]
39. Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.
Sun MK; Alkon DL
CNS Drug Rev; 2006; 12(1):1-8. PubMed ID: 16834754
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic modulators from "The Big Blue": a treasure to fight against cancer.
Schnekenburger M; Dicato M; Diederich M
Cancer Lett; 2014 Sep; 351(2):182-97. PubMed ID: 24964131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
